E-Mail
IMAGE: Under FDA emergency-use authorization, doctors successfully resolved COVID-19 in a seriously ill, immunodeficient woman using a very high-neutralizing antibody-titer convalescent plasma from a recovered COVID-19 patient. However, further study suggested. view more
Credit: UAB
BIRMINGHAM, Ala. - A 72-year-old woman was hospitalized with severe COVID-19 disease, 33 days after the onset of symptoms. She was suffering a prolonged deteriorating illness, with severe pneumonia and a high risk of death, and she was unable to mount her own immune defense against the SARS-CoV-2 virus because of chronic lymphocytic leukemia, which compromises normal immunoglobulin production.
But when physicians at the University of Alabama at Birmingham recommended a single intravenous infusion of convalescent blood plasma from her son-in-law who had recovered from COVID-19 disease a remarkable, beneficial change followed. Her physician, Randall Davis, M.D., professor in the
Study: Individuals recovering from COVID-19 helpful for Sustained cellular immune dysregulation ANI | Updated: Jan 03, 2021 22:10 IST
Birmingham [UK], January 3 (ANI): A recent study has determined that Covid-19 patients might be helpful for clinicians to better understand how the unknown SARS-CoV-2 virus acts.
According to a study published in the Journal of Clinical Investigation, many infected patients remain asymptomatic or have mild symptoms. Others, especially those with comorbidities, can develop severe clinical disease with atypical pneumonia and multiple system organ failures.
Since the first cases were reported in December 2019, the SARS-CoV-2 virus that causes COVID-19 has surged into a pandemic, with cases and deaths still mounting. Ongoing observational clinical research has become a priority to better understand how this previously unknown virus acts, and findings from this research can better inform treatment and vaccine desig
Study finds sustained cellular immune dysregulation in patients recovering from COVID-19 ANI | Updated: Jan 02, 2021 23:14 IST
Birmingham [UK], January 2 (ANI): Findings from recent researches on COVID-19 and observational clinical research of COVID-19 patients can help clinicians explore more about the virus to better inform treatment and vaccine design.
The University of Alabama at Birmingham researchers, led by first-author Jacob Jake Files and co-senior authors Nathan Erdmann, M.D., PhD, and Paul Goepfert, M.D., have now reported their observational study, Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection, published in the Journal of Clinical Investigation.
COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path. Many infected patients remain asymptomatic or have mild symptoms. Others, especially those with comorbidities, can develop severe clinical disease wit
Sustained cellular immune dysregulation in COVID patients birminghamstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from birminghamstar.com Daily Mail and Mail on Sunday newspapers.
Jacob “Jake” Files COVID-19, which has killed 1.7 million people worldwide, does not follow a uniform path.
Many infected patients remain asymptomatic or have mild symptoms. Others, especially those with comorbidities, can develop severe clinical disease with atypical pneumonia and multiple system organ failure.
Since the first cases were reported in December 2019, the SARS-CoV-2 virus that causes COVID-19 has surged into a pandemic, with cases and deaths still mounting. Ongoing observational clinical research has become a priority to better understand how this previously unknown virus acts, and findings from this research can better inform treatment and vaccine design.
University of Alabama at Birmingham researchers, led by first-author Jacob “Jake” Files and co-senior authors Nathan Erdmann, M.D., Ph.D., and Paul Goepfert, M.D., have now reported their observational study, “Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infectio